-
公开(公告)号:US20100173013A1
公开(公告)日:2010-07-08
申请号:US12684053
申请日:2010-01-07
申请人: Denis Drygin , Kenna Anderes , Caroline B. Ho , Joshua R. Bliesath , Christopher B. Proffitt , Sean O'Brien , William G. Rice
发明人: Denis Drygin , Kenna Anderes , Caroline B. Ho , Joshua R. Bliesath , Christopher B. Proffitt , Sean O'Brien , William G. Rice
IPC分类号: A61K31/4375 , A61K31/519 , A61K33/24 , A61K31/675 , A61K31/5377 , A61P35/00 , A61P37/06 , A61K31/704 , A61K31/7076 , A61K31/7068 , A61K31/517 , A61K31/437
CPC分类号: A61K45/06 , A61K31/337 , A61K31/35 , A61K31/395 , A61K31/404 , A61K31/4045 , A61K31/436 , A61K31/4375 , A61K31/44 , A61K31/4745 , A61K31/475 , A61K31/498 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/704 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K2300/00
摘要: The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.
摘要翻译: 本申请一般涉及用于治疗肿瘤性疾病的组合疗法的化合物,组合物和方法。
-
2.Biomarkers for predicting the sensitivity and response of protein kinase CK2-mediated diseases to CK2 Inhibitors 审中-公开
标题翻译: 用于预测蛋白激酶CK2介导的疾病对CK2抑制剂的敏感性和反应的生物标志物公开(公告)号:US20110212845A1
公开(公告)日:2011-09-01
申请号:US12897640
申请日:2010-10-04
申请人: Denis DRYGIN , Sean E. O'BRIEN , Kenna L. ANDERES , Daniel VON HOFF , John K.C. LIM , Claire S. PADGETT , Joshua R. BLIESATH , Caroline B. HO , William G. Rice
发明人: Denis DRYGIN , Sean E. O'BRIEN , Kenna L. ANDERES , Daniel VON HOFF , John K.C. LIM , Claire S. PADGETT , Joshua R. BLIESATH , Caroline B. HO , William G. Rice
CPC分类号: G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/574 , G01N2333/91205 , G01N2440/14 , G01N2800/52
摘要: Disclosed are biomarkers for determining the sensitivity of protein kinase CK2-mediated diseases, such as proliferative and/or inflammatory disorders, to treatment with CK2 inhibitors. These biomarkers can be used to predict or select subjects likely to be responsive to treatment with a CK2 inhibitor, and to treat or monitor subjects undergoing treatment with a CK2 inhibitor.
摘要翻译: 公开了用于确定蛋白激酶CK2介导的疾病如增殖性和/或炎症性疾病对用CK2抑制剂治疗的敏感性的生物标志物。 这些生物标志物可用于预测或选择可能对CK2抑制剂治疗有反应的受试者,以及治疗或监测接受CK2抑制剂治疗的受试者。
-